for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Pfizer Inc.

PFE

Latest Trade

38.33USD

Change

-0.15(-0.39%)

Volume

11,561,154

Today's Range

38.22

 - 

38.66

52 Week Range

27.88

 - 

40.97

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
38.48
Open
38.61
Volume
11,561,154
3M AVG Volume
660.07
Today's High
38.66
Today's Low
38.22
52 Week High
40.97
52 Week Low
27.88
Shares Out (MIL)
5,554.83
Market Cap (MIL)
213,750.00
Forward P/E
13.33
Dividend (Yield %)
3.95

Next Event

Pfizer Inc Investor Day

Latest Developments

More

Kymera Therapeutics Inc Files For IPO Of Up To $100 Million - SEC Filing

Pfizer Reports Q2 Adjusted Earnings Per Share $0.78

Biontech Announces Proposed Public Offerings

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Pfizer Inc.

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. Its brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra.

Industry

Biotechnology & Drugs

Contact Info

235 E 42ND ST

NEW YORK, NY

10017-5703

United States

+1.212.5732323

https://www.pfizer.com/

Executive Leadership

Albert Bourla

Chairman of the Board, Chief Executive Officer

John D. Young

Chief Business Officer, Group President

Frank A. D'Amelio

Chief Financial Officer, Executive Vice President - Business Operations and Global Supply

Angela Hwang

Group President, Pfizer Biopharmaceuticals Group

Dawn Rogers

Chief Human Resource Officer, Executive Vice President

Key Stats

2.53 mean rating - 17 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

52.5K

2018

53.6K

2019

51.8K

2020(E)

49.5K
EPS (USD)

2017

2.650

2018

3.000

2019

2.950

2020(E)

2.933
Price To Earnings (TTM)
14.06
Price To Sales (TTM)
4.22
Price To Book (MRQ)
3.29
Price To Cash Flow (TTM)
10.09
Total Debt To Equity (MRQ)
80.41
LT Debt To Equity (MRQ)
55.79
Return on Investment (TTM)
12.02
Return on Equity (TTM)
9.63

Latest News

Latest News

Pfizer, BioNTech to supply 120 million doses of coronavirus vaccine to Japan

Pfizer Inc <PFE.N> and BioNTech SE <BNTX.O> have agreed to supply Japan with 120 million doses of their experimental coronavirus vaccine in the first half of 2021, the companies said on Friday.

Pfizer, BioNTech to supply 120 mln doses of coronavirus vaccine to Japan

Pfizer Inc and BioNTech SE have agreed to supply Japan with 120 million doses of their mRNA-based vaccine candidate against the novel coronavirus in the first half of 2021, the companies said on Friday.

Pfizer says it will charge other developed countries on par with U.S. for vaccine deals

Pfizer Inc <PFE.N> on Tuesday said other developed countries would not get a lower price for its coronavirus vaccine than what it will charge the United States under a contract announced last week, and suggested that people may need multiple vaccinations in order to remain...

Pfizer CEO says negotiating with EU on contract for COVID-19 vaccine: interview

Drugmaker Pfizer Inc <PFE.N> is in concurrent talks with the European Union as well as several of its member states to sell them the COVID-19 vaccine candidate it is developing, Chief Executive Albert Bourla said in an interview on Tuesday.

Pfizer CEO says negotiating with EU on contract for COVID-19 vaccine-interview

Drugmaker Pfizer Inc is in concurrent talks with the European Union as well as several of its member states to sell them the COVID-19 vaccine candidate it is developing, Chief Executive Albert Bourla said in an interview on Tuesday.

CORRECTED-Pfizer profit falls 32% as global trial of COVID-19 vaccine candidate begins

Pfizer Inc reported a 32% fall in second-quarter profit on Tuesday due to a dip in demand for some of its drugs from the COVID-19 pandemic and from rising competition, as the company and partner began a global study into a vaccine candidate to fight the health crisis.

Pfizer rethinking U.S. expansion if drug pricing orders implemented

Pfizer Inc <PFE.N> Chief Executive Albert Bourla said the drugmaker could rethink plans to expand in the United States if the country implements an executive order signed by President Donald Trump last week that would tie the prices Medicare patients pay for drugs to those...

Pfizer rethinking U.S. expansion if drug pricing orders implemented

Pfizer Inc Chief Executive Albert Bourla said the drugmaker could rethink plans to expand in the United States if the country implements an executive order signed by President Donald Trump last week that would tie the prices Medicare patients pay for drugs to those paid...

Moderna, Pfizer start decisive COVID-19 vaccine trials, eye year-end launches

Moderna Inc <MRNA.O> and Pfizer Inc <PFE.N> launched two 30,000-subject trials of COVID-19 vaccines that could clear the way for regulatory approval and widespread use by the end of this year, the companies said on Monday.

Pfizer-BioNTech begin late-stage study of lead COVID-19 vaccine candidate

German biotech BioNTech and U.S. drugmaker Pfizer Inc said on Monday they would begin a pivotal global study to evaluate their lead COVID-19 vaccine candidate.

Pfizer-BioNTech begin global study of lead COVID-19 vaccine candidate

German biotech BioNTech and U.S. drugmaker Pfizer Inc said on Monday they would begin a global study to evaluate their lead COVID-19 vaccine candidate.

Exclusive: EU talks with Pfizer, Sanofi, J&J on COVID vaccines hit snags - sources

European efforts to secure potential COVID-19 vaccines from Pfizer <PFE.N>, Sanofi <SASY.PA> and Johnson & Johnson <JNJ.N> are mired in wrangles over price, payment method and potential liability costs, three EU officials told Reuters.

Brazil eyes buying Pfizer vaccine to be tested in country

Brazil is looking into acquiring doses of a potential coronavirus vaccine under development by Pfizer Inc, which will be tested in the country, Interim Health Minister Eduardo Pazuello said on Wednesday.

Breakingviews - Corona Capital: Thanksgiving shopping, Airlines

Corona Capital is a daily column updated throughout the day by Breakingviews columnists around the world with short, sharp pandemic-related insights.

U.S. to pay Pfizer, BioNTech $1.95 billion for COVID-19 vaccine

The U.S. government will pay nearly $2 billion to buy enough of a COVID-19 vaccine being developed by Pfizer Inc <PFE.N> and German biotech BioNTech SE <22UAy.F> to innoculate 50 million people if it proves to be safe and effective, the companies said on Wednesday.

U.S. has contract with Pfizer for 100 million coronavirus vaccine doses: Azar

U.S. Health and Human Services Secretary Alex Azar said on Wednesday the federal government has signed a contract with Pfizer Inc. <PFE.N> for 100 million doses of coronavirus vaccine, once it is approved.

UPDATE 1-U.S. has contract with Pfizer for 100 mln coronavirus vaccine doses -Azar

U.S. Health and Human Services Secretary Alex Azar said on Wednesday the federal government has signed a contract with Pfizer Inc for 100 million doses of coronavirus vaccine, once it is approved.

Moderna, Merck say they will not limit price of coronavirus vaccines to company cost

Moderna Inc and Merck & Co on Tuesday told a U.S. Congressional panel that they expect to profit from their coronavirus vaccines once approved, amid concerns the vaccines may not be accessible to all.

Pfizer-BioNTech potential coronavirus vaccine shows promise in second early trial

German biotech BioNTech and U.S. drugmaker Pfizer Inc on Monday said data from an early-stage trial of their experimental coronavirus vaccine showed that it prompted an immune response and was well-tolerated, similar to results seen in prior early test.

Britain secures 90 million possible COVID-19 vaccine doses from Pfizer/BioNTech, Valneva

Britain has signed deals to secure 90 million doses of two possible COVID-19 vaccines from an alliance of Pfizer Inc <PFE.N> and BioNTech <22UAy.F>, and French group Valneva <VLS.PA>, the business ministry said on Monday.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up